REFERENCES
- Sewell K, Schein JR. Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects. Semin. Arthritis Rheum. 2001; 30: 288–297
- Baker DE. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Rev. Gastroenterol. Disord. 2002; 2: 20–33
- Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999; 25: 97–106
- Song Y, Wang Y, Thakur R, Meidan VM, Michniak B. Mucosal drug delivery: membranes, methodologies, and applications. Crit. Rev. Ther. Drug. Carrier Syst. 2004; 21: 195–256
- Taha EI, Zaghloul AA, Samy AM, Al-Saidan S, Kassem AA, Khan MA. Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. Int. J. Pharm. 2004; 279: 3–7
- Berkó S, Regdon G, Ducza E, Falkay G, Erós I. In vitro and in vivo study in rats of rectal suppositories containing furosemide. Eur. J. Pharm. Biopharm. 2002; 53: 311–315
- de Boer AG, Moolenaar F, de Leede LGJ, Breimer DD. Rectal drug administration: clinical pharmacokinetics consideration. Clin. Pharmacokin. 1982; 7: 285–311
- Umeda T, Matsuzawa A, Yokoyama T, Kuroda K, Kuroda T. Studies on sustained release dosage forms. I. Preparation of indomethacin suppositories. Chem. Pharm. Bull. 1983; 31: 2793–2798
- Nakajima T, Takashima Y, Iida K, Mitsuta H, Koishi M. Preparation and in vitro evaluation of sustained-release suppositories containing microencapsulated indomethacin. Chem. Pharm. Bull. 1987; 35: 1201–1206
- El-Shanawany S, Aly SAR. Formulation of propranolol hydrochloride suppositories and pharmacological evaluation in rabbits. Eur. J. Pharm. Biopharm. 1994; 40: 327–332
- Babar A, Bellete T, Plakogiannis FM. Ketoprofen suppository dosage forms: in vitro release and in vivo absorption studies in rabbits. Drug Dev. Ind. Pharm. 1999; 25: 241–245
- Takatori T, Shimono N, Higaki K, Kimura T. Evaluation of sustained release suppositories prepared with fatty base including solid fats with high melting points. Int. J. Pharm. 2004; 278: 275–282
- Puffer HW, Crowell WJ. Salicylate release characteristics of selected polyethylene glycol suppositories. J. Pharm. Sci. 1973; 62: 242
- Perkins AC, Wilson CG, Frier M, et al. The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water. Int. J. Pharm. 2001; 222: 295–303
- Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int. J. Pharm. 1999; 180: 185–193
- Davis SS, Hardy JG, Newman SP, Wilding IR. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur. J. Nucl. Med. 1992; 19: 971–986
- Aşıkoğlu M, Ertan G, Ercan MT, Duman Y. The release of isoconazole nitrate from different suppository bases: in-vivo release of drug labelled with 99mTc in rabbits. J. Pharm. Pharmacol. 1995; 47: 717–720
- Digenis GA, Sandefer EP, Page RC, Doll WJ. Gamma scintigraphy: an evolving technology in pharmaceutical formulation development: part 1. Pharm. Sci. Technol. Today. 1998; 1: 100–108
- Perkins AC, Frier M. Nuclear medicine techniques in the evaluation of pharmaceutical formulations. Pharm. World Sci. 1996; 18: 97–104
- Wilding R, Coupe AJ, Davis SS. The role of gamma;-scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. 2001; 46: 103–124
- Noguera EC, Jaime A, Veliz J, Nicolini J, Ugetti R. Bone scintigraphy with 99mTc-Alendronate: a potential bone imaging agent in place of other bisphosphonates. The 8th Congress of the World Federation of Nuclear Medicine & Biology; 2002. Abstract 142, Revista Medicina Nuclear Alasbimn Journal 5
- de Murphy CA, Ferro-Flores G, Pedraza-López M, et al. Labelling of Re-ABP with 188Re for bone pain palliation. Appl. Radiat. Isot. 2001; 54: 435–442
- Aşıkoğlu M, Ertan G, Cosar G. The release of isoconazole nitrate from different suppository bases: in-vitro dissolution, physicochemical and microbiological studies. J. Pharm. Pharmacol. 1995; 47: 713–716
- Lin JH. Bisphosphanates: a rewiew of their pharmacokinetic properties. Bone. 1996; 18: 75–85
- Montoya-Molina CE, Sepúlveda-Méndez J, de-Murphy CA, Meléndez-Alafort L, Rojas-Bautista JC, López-Alvarenga JC. 99m-Tc alendronate as a new option in bone gammagraphy. Revista De Investigación Clinica; Organo Del Hospital De Enfermedades De La Nutricion. 1997; 49: 373–377
- de Murphy CA, Meléndez-Alafort L, Montoya-Molina CE, Sepúlveda-Méndez J. Technetium-99m-alendronate: a new radiopharmaceutical for bone scanning. Arch. Med. Res. 1996; 27: 481–483
- de Murphy CA, Meléndez-Alafort L, Montoya-Molina CE, Sepúlveda-Méndez J. Radiopharmacokinetic data for 99mTc-ABP a new radiopharmaceutical for bone scanning: comparison with 99mTc-MDP. Nucl. Med. Biol. 1997; 24: 27–33
- Jost RC. WB Hladik, GB Saha, KT StudyMetabolic fate of radiopharmaceuticals. Essentials of Nuclear Medicine Science, . Williams & Wilkins, Baltimore, Md 1987; 44–50
- Wang D, Miller SC, Sima M, Kopecková P, Kopecek J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjugate Chem. 2003; 14: 853–859
- Wang D, Miller SC, Kopecková P, Kopecek J. Bone-targeting macromolecular therapeutics. Adv. Drug Deliv. Rev. 2005; 57: 1049–1076